iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Auro Pharma stock surges 4% despite 79.5% yoy decline in Q3 profit at Rs604.3 crore

10 Feb 2022 , 12:08 PM

Aurobindo Pharma

Aurobindo Pharma Limited reported a sharply lower 79.5% yoy profit at Rs604.3cr in the quarter ended December 31, 2021 (Q3FY22) against Rs2,947.9cr in Q3FY21. The company’s revenue declined 1% yoy to Rs6,002cr from Rs6,364.9cr yoy.

US formulations revenue declined by 13.4% on a yoy basis to Rs2,745.2cr.  Europe formulation revenue stood at Rs1,694cr, an increase of 1.4% over the corresponding previous quarter. Growth Markets grew by 2.8% qoq to Rs397cr. ARV revenue improved by 7.4% qoq to Rs156cr. API revenue for the quarter was at Rs1,010cr vs. Rs682.5cr in the corresponding previous period.

EBIDTA before Forex and Other income stood at Rs1,016.3cr; EBITDA margin for the quarter was 16.9%. Research & Development (R&D) spend at Rs393cr, 6.6% of revenues (Q2 FY22: 6.7%). Received final approval for 4 ANDAs including 1 injectable product from the USFDA. Basic & Diluted EPS is Rs10.32 per share.

The company stock was in demand on Thursday. At around 12.10 pm, Aurobindo Pharma Ltd was trading at Rs682.50 per share up by Rs27.25 or 4.16% from its previous closing of Rs655.25 per share on the BSE.

K Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “The quarter’s performance was impacted by high input and freight costs, that weighed on profitability. However, our business was resilient in delivering steady revenues, led by API business benefitting from improved demand for our key products.

We made progress in optimizing our working capital during the quarter that has strengthened our balance sheet further. We remain committed to resolve the regulatory issues affecting some of our facilities and are continuing to make steady progress in our complex generic product development plans. As a company, we are focused on executing on our key growth drivers to drive sustained improvement in profitability and enhance stakeholder value.”

Related Tags

  • Auro Pharma news
  • Auro Pharma results
  • Auro Pharma share price
  • Auro Pharma stock price
  • Aurobindo Pharma Limited
  • profit
  • Q3FY22
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.